The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes
Open accessAbstract
Elevated levels of the p53 protein occur in ∼50% of human malignancies, which makes it an excellent target for a broad-spectrum T cell immunotherapy of cancer. A major barrier to the design of p53-specific immunotherapeutics and vaccines, however, is the possibility that T cells may be tolerant of antigens derived from wild-type p53 due to its low level of expression in normal thymus and lymphohemopoetic cells. The combination of p53 deficient (p53−/−) and p53+/+ HLA-A2.1/Kb transgenic mice was used as a model to explore the possibility that A2.1restricted cytotoxic T lymphocytes (CTL) are functionally tolerant of self peptides derived from the wild-type p53 tumor suppressor protein. A2.1-restricted CTL specific for a naturally processed p53 self-epitope spanning residues 187-197 were completely aborted in p53+/+ as opposed to p53−/− transgenic mice. In contrast, CTL specific for a second self-epitope spanning residues 261-269 of the murine p53 sequence were detected in both p53−/− and p53+/+ A2.1/Kb transgenic mice. However, the avidity of the CTL effectors obtained from p53+/+ mice was 10-fold lower than that obtained from p53−/− mice, again suggesting elimination of CTL with high avidity for the A2.1-peptide complex. The circumvention of functional tolerance of high avidity CTL may therefore be a necessary prerequisite for optimizing immunotherapy against A2.1-restricted wild-type p53 epitopes in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
T cell receptor antagonist peptides induce positive selection
Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J., & Carbone, F. R. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 2,858
Thymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
T cell tolerance by clonal elimination in the thymus
Kappler, J. W., Roehm, N., & Marrack, P. (1987) · Cell · doi:10.1016/0092-8674(87)90568-x · Cited by 2,211
Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes
Kisielow, P., Blüthmann, H., Staerz, U. D., Steinmetz, M., & von Boehmer, H. (1988) · Nature · doi:10.1038/333742a0 · Cited by 1,682
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
T-cell receptor Vβ use predicts reactivity and tolerance to Mlsa- encoded antigens
MacDonald, H. R., Schneider, R., Lees, R. K., Howe, R. C., Acha-Orbea, H., Festenstein, H., Zinkernagel, R. M., & Hengartner, H. (1988) · Nature · doi:10.1038/332040a0 · Cited by 888
Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J. M., Oseroff, C., Yuan, L., Ruppert, J., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.12.5586 · Cited by 830
Evidence for a differential avidity model of T cell selection in the thymus
Ashton-Rickardt, P. G., Bandeira, A., Delaney, J. R., Van Kaer, L., Pircher, H.-P., Zinkernagel, R. M., & Tonegawa, S. (1994) · Cell · doi:10.1016/0092-8674(94)90505-3 · Cited by 668
Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 476
Rearrangement of the p53 gene in human osteogenic sarcomas.
Masuda, H., Miller, C., Koeffler, H. P., Battifora, H., & Cline, M. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7716 · Cited by 474
Harvey, D. M., & Levine, A. J. (1991) · Genes & Development · doi:10.1101/gad.5.12b.2375 · Cited by 453
Low avidity recognition of self-antigen by T cells permits escape from central tolerance
Liu, G. Y., Fairchild, P. J., Smith, R. M., Prowle, J. R., Kioussis, D., & Wraith, D. C. (1995) · Immunity · doi:10.1016/1074-7613(95)90170-1 · Cited by 413
p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors.
Rogel, A., Popliker, M., Webb, C. G., & Oren, M. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.10.2851 · Cited by 378
Vitiello, A., Marchesini, D., Furze, J., Sherman, L. A., & Chesnut, R. W. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.4.1007 · Cited by 311
Self-citationHow virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model
von Herrath, M. G., Dockter, J., & Oldstone, M. B. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90101-5 · Cited by 304
Targeting p53 as a general tumor antigen.
Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., & Sherman, L. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.11993 · Cited by 304
Self-citationLehner, P. J., Wang, E. C., Moss, P. A., Williams, S., Platt, K., Friedman, S. M., Bell, J. I., & Borysiewicz, L. K. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.79 · Cited by 258
Houbiers, J. G. A., Nijman, H. W., Van Der Burg, S. H., Drijfhout, J. W., Kenemans, P., Van De Velde, C. J. H., Brand, A., Momburg, F., Kast, W. M., & Melief, C. J. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230905 · Cited by 258
Lower receptor avidity required for thymic clonal deletion than for effector T-cell function
Pircher, H., Rohrer, U. H., Moskophidis, D., Zinkernagel, R. M., & Hengartner, H. (1991) · Nature · doi:10.1038/351482a0 · Cited by 254
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
Mayordomo, J. I., Loftus, D. J., Sakamoto, H., De Cesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., & DeLeo, A. B. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1357 · Cited by 253
Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2
PARHAM, P., & BODMER, W. F. (1978) · Nature · doi:10.1038/276397a0 · Cited by 236
Autoimmune diabetes as a consequence of locally produced interleukin-2
Heath, W. R., Allison, J., Hoffmann, M. W., Schönrich, G., Hämmerling, G., Arnold, B., & Miller, J. F. A. P. (1992) · Nature · doi:10.1038/359547a0 · Cited by 236
Hébert, L. J., Maltais, D. B., Lepage, C., Saulnier, J., Crête, M., & Perron, M. (2011) · Pediatric Physical Therapy · doi:10.1097/pep.0b013e318227ccff · Cited by 227
Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.
Noguchi, Y., Richards, E. C., Chen, Y. T., & Old, L. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.6.2219 · Cited by 212
Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53.
Harlow, E., Williamson, N. M., Ralston, R., Helfman, D. M., & Adams, T. E. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.7.1601 · Cited by 174
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
Noguchi, Y., Chen, Y. T., & Old, L. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3171 · Cited by 173
Shirai, M., Arichi, T., Nishioka, M., Nomura, T., Ikeda, K., Kawanishi, K., Engelhard, V. H., Feinstone, S. M., & Berzofsky, J. A. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.6.2733 · Cited by 165
Hogquist, K. A., Jameson, S. C., & Bevan, M. J. (1995) · Immunity · doi:10.1016/1074-7613(95)90160-4 · Cited by 158
Peptides in positive and negative selection: A delicate balance
Allen, P. M. (1994) · Cell · doi:10.1016/0092-8674(94)90497-9 · Cited by 152
Irwin, M. J., Heath, W. R., & Sherman, L. A. (1989) · The Journal of Experimental Medicine · doi:10.1084/jem.170.4.1091 · Cited by 136
Self-citationRoth, J., Dittmer, D. P., Réa, D., Tartaglia, J., Paoletti, E., & Levine, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4781 · Cited by 118
Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes
Milner, J. (1984) · Nature · doi:10.1038/310143a0 · Cited by 116
Schaeffer, E. B., Sette, A., Johnson, D. L., Bekoff, M. C., Smith, J. A., Grey, H. M., & Buus, S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.12.4649 · Cited by 111
Alexander, M., Damico, C. A., Wieties, K., Hansen, T. H., & Connolly, J. M. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.4.849 · Cited by 111
Speiser, D. E., Kyburz, D., Stübi, U., Hengartner, H., & Zinkernagel, R. M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.3.972 · Cited by 102
Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancer
Tilkin, A. F., Lubin, R., Soussi, T., et al. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250642 · Cited by 99
Peripheral Tolerance as a Multi‐Step Mechanism
Hämmerling, G. J., Schönrich, G., Ferber, I., & Arnold, B. (1993) · Immunological Reviews · doi:10.1111/j.1600-065x.1993.tb01511.x · Cited by 95
Sun, J., Leahy, D. J., & Kavathas, P. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.5.1275 · Cited by 92
von Herrath, M. G., Dockter, J., Nerenberg, M. I., Gairin, J. E., & Oldstone, M. B. A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.5.1901 · Cited by 87
p53, a potential target for tumor-directed T cells
Nijman, H. W., van der Burg, S. H., Vicrboom, M. P. M., Houbiers, J. G. A., Kast, W. M., & Melief, C. J. M. (1994) · Immunology Letters · doi:10.1016/0165-2478(94)90189-9 · Cited by 86
Mortarini, R., Belli, F., Parmiani, G., & Anichini, A. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450221 · Cited by 81
p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency.
Benveniste, P. M., & Cohen, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.18.8373 · Cited by 75
Terada, N., Lucas, J. J., & Gelfand, E. W. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.2.698 · Cited by 69
Antigen‐presenting Cells for CD8+ T Cells
Sprent, J., & Schaefer, M. E. (1990) · Immunological Reviews · doi:10.1111/j.1600-065x.1990.tb00574.x · Cited by 56
A Transgenic Approach to the Study of Peripheral T‐Cell Tolerance
Miller, J. F. A. P., Morahan, G., Allison, J., & Hoffmann, M. (1991) · Immunological Reviews · doi:10.1111/j.1600-065x.1991.tb00599.x · Cited by 51
Human CD8 transgene regulation of HLA recognition by murine T cells.
LaFace, D., Vestberg, M., Yang, Y., Srivastava, R., Santo, J. P. D., Flomenberg, N., Brown, S. L., Sherman, L. A., & Peterson, P. A. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.5.1315 · Cited by 43
Self-citationTCR-mediated death of mature T lymphocytes occurs in the absence of p53
Boehme, S. A., & Lenardo, M. J. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.11.4075 · Cited by 38
O’Neil, B. H., Kawakami, Y., Restifo, N. P., Bennink, J. R., Yewdell, J. W., & Rosenberg, S. A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.3.1410 · Cited by 35
Cited by
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
Bendle, G. M., Linnemann, C., Hooijkaas, A. I., Bies, L., de Witte, M. A., Jorritsma, A., Kaiser, A. D. M., Pouw, N., Debets, R., Kieback, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2128 · Cited by 448
Bos, R., & Sherman, L. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1322 · Cited by 443
Self-citationYee, C., Savage, P. A., Lee, P. P., Davis, M. M., & Greenberg, P. D. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2227 · Cited by 415
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer
Stanislawski, T., Voss, R.-H., Lotz, C., Sadovnikova, E., Willemsen, R. A., Kuball, J., Ruppert, T., Bolhuis, R. L. H., Melief, C. J., Huber, C., et al. (2001) · Nature Immunology · doi:10.1038/ni1001-962 · Cited by 362
Self-citation
Metadata
- Authors
- Theobald, M., Biggs, J., Hernández, J., Lustgarten, J., Labadie, C., & Sherman, L. A.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1997-03-03
- Volume
- 185
- Issue
- 5
- Pages
- 833-842
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2078760290
- Cited by
- 256
- References
- 52
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.